AEterna Zentaris has received $52.5 million from Cowen Healthcare Royalty Partners (CHRP) at closing, less certain transaction costs. Under the terms of the agreement with CHRP, AEterna Zentaris would receive an additional payment of $2.5 million from CHRP contingent on 2010 net sales of Cetrotide reaching a specified level.
Cetrotide (cetrorelix) was the first luteinizing hormone-releasing hormone antagonist treatment approved for in vitro fertilization. It is administered to women to prevent premature ovulation in order to increase fertility success rate.